188 related articles for article (PubMed ID: 32253706)
1. Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations.
Das A; Alshareef M; Martinez Santos JL; Porto GBF; McDonald DG; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Clin Transl Oncol; 2020 Nov; 22(11):2017-2025. PubMed ID: 32253706
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
4. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
6. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
7. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
8. Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
Cao J; Zhu Z; Wang H; Nichols TC; Lui GYL; Deng S; Rejto PA; VanArsdale T; Hardwick JS; Weinrich SL; Wei P
Oncogene; 2019 May; 38(21):4125-4141. PubMed ID: 30700828
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
Rocca A; Farolfi A; Bravaccini S; Schirone A; Amadori D
Expert Opin Pharmacother; 2014 Feb; 15(3):407-20. PubMed ID: 24369047
[TBL] [Abstract][Full Text] [Related]
11. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
Malorni L; Piazza S; Ciani Y; Guarducci C; Bonechi M; Biagioni C; Hart CD; Verardo R; Di Leo A; Migliaccio I
Oncotarget; 2016 Sep; 7(42):68012-68022. PubMed ID: 27634906
[TBL] [Abstract][Full Text] [Related]
12. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
[TBL] [Abstract][Full Text] [Related]
13. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
Arnedos M; Bayar MA; Cheaib B; Scott V; Bouakka I; Valent A; Adam J; Leroux-Kozal V; Marty V; Rapinat A; Mazouni C; Sarfati B; Bieche I; Balleyguier C; Gentien D; Delaloge S; Lacroix-Triki M; Michiels S; Andre F
Ann Oncol; 2018 Aug; 29(8):1755-1762. PubMed ID: 29893769
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
[TBL] [Abstract][Full Text] [Related]
17. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest.
Francis AM; Alexander A; Liu Y; Vijayaraghavan S; Low KH; Yang D; Bui T; Somaiah N; Ravi V; Keyomarsi K; Hunt KK
Mol Cancer Ther; 2017 Sep; 16(9):1751-1764. PubMed ID: 28619757
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas.
Göttgens EL; Bussink J; Leszczynska KB; Peters H; Span PN; Hammond EM
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):548-558. PubMed ID: 31271827
[TBL] [Abstract][Full Text] [Related]
20. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
